IL6 and renal carcinoma: A monoclonal antibody, CNTO 328 (siltuximab) inhibits JAK/STAT3 signaling and IL-6/IL-6R/gp130 trans-signaling by interfering with the binding of IL-6 and IL-6R and has shown encouraging results in early trials in ovarian and renal cancers [296,297,298].